Linda-Gail Bekker's HIV Vaccine Hope

This is a US news story, published by Wired, that relates primarily to Bekker news.

US news

For more US news, you can click here:

more US news

Bekker news

For more Bekker news, you can click here:

more Bekker news

drug discoveries news

For more drug discoveries news, you can click here:

more drug discoveries news

Wired news

For more news from Wired, you can click here:

more news from Wired

About the Otherweb

Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about

HIV treatments

. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest antiretroviral treatments news, HIV prevention news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!

HIV experts

Wired

•

Health

This New Drug Could Help End the HIV Epidemic—but US Funding Cuts Are Killing Its Rollout

Summary

Nutrition label

75% Informative

HIV experts had dreamed of an elusive vaccine to block the ongoing chain of infections, which still sees more than 1 million people worldwide contract the virus annually .

But now, thanks to the Trump administration's executive orders, it’s unclear when—or possibly even ever—this breakthrough medicine will see the light of day .

To prevent over a million new infections each year , these jabs need to be targeted at HIV hotspots and administered on a scale of millions .

Gilead has partnered with six generic drugmakers who have been licensed to produce enough of an off-label supply of lenacapavir to cover 120 countries.

Many studies were expected to be funded by US resources.

Many of these studies are now in doubt, as PEPFAR restrictions have been placed on other types of research funding.

Bekker is exploring new options for funding HIV prevention and research through European agencies.

At the same time, she believes that African countries need to become capable of funding more preventative efforts.

VR Score

Informative language

Neutral language

Article tone

semi-formal

Language

English

Language complexity